CorMedix Reports Positive Interim Results from Real-World DefenCath Study in Hemodialysis Patients
I'm PortAI, I can summarize articles.
CorMedix Inc. announced positive interim results from its real-world study of DefenCath in hemodialysis patients, showing a reduction in serious infections and hospitalizations. The study, in collaboration with U.S. Renal Care, began after DefenCath's commercial launch in July 2024. Data from 7,000 patients indicate promising outcomes, with further results expected. CorMedix is using this data to support broader access and reimbursement discussions.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments